GSK Lotronex Indication Suggests Potential Market Of $280 Mil.
Executive Summary
GlaxoSmithKline's narrowed Lotronex indication gives the product a potential market approximately the size of the company's U.S. hepatitis vaccine market in 2001
You may also be interested in...
Can Prometheus Light A Fire Under Lotronex? GI Specialty Firm Will Add Reps
Prometheus Laboratories has lofty expectations for Lotronex (alosetron), the irritable bowel syndrome drug it is acquiring from GlaxoSmithKline
Can Prometheus Light A Fire Under Lotronex? GI Specialty Firm Will Add Reps
Prometheus Laboratories has lofty expectations for Lotronex (alosetron), the irritable bowel syndrome drug it is acquiring from GlaxoSmithKline
GSK Lotronex Risk Management Program Allows For Off-Label Use
GlaxoSmithKline will track prescriptions for Lotronex to gauge use of the irritable bowel syndrome therapy outside of the risk management program